Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral ...

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Ireland's government and pharmaceutical sector have broadly welcomed the European Council's 'pharma package' agreement, but opposition remains in Dublin over potential delays to affordable drugs.

According to Benzinga Pro, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.58%, which means the company has less short interest than most of its peers.

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

On May 21, 2025, the Federal Trade Commission (FTC) issued its third round of warning letters – and its first under the Trump administration – ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International ...